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Abstract 
Stable Mn
2+
 mono- and binuclear complexes containing pentadentate 6,6′-((methylazanediyl)bis(methylene)) 
dipicolinic acid coordinating units give remarkably high relaxivities due to the presence of two inner-sphere 
water molecules. The mononuclear derivative binds human serum albumin (HSA) with an association 
constant of 3372 M−1, which results in the replacement of the coordinated water molecules by donor atoms of 
protein residues. The dinuclear analogue also binds HSA while leaving one of the Mn
2+
 centres exposed to 
the solvent with two coordinated water molecules. Thus, this complex shows remarkably high relaxivities 
upon protein binding (39.0 mM
−1 s−1 per Mn, at 20 MHz and 37 °C). 
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Introduction 
Stable high-spin Mn
2+
 complexes represent an attractive alternative to the classical Gd
3+
-based contrast 
agents (CAs) for application in magnetic resonance imaging (MRI).
[1, 2] 
CAs are paramagnetic species that 
enhance the contrast between a specific tissue or organ of interest and the surrounding tissues of the body, 
thus increasing the diagnostic accuracy of the technique and shortening the examination time. All Gd
3+
-based 
CAs that have entered clinical practice are complexes with poly(aminocarboxylate) ligands with high 
thermodynamic and often kinetic stability. These agents present a single water molecule coordinated to the 
paramagnetic ion that exchanges sufficiently rapidly with the bulk water, thereby accelerating the 
longitudinal and/or transverse relaxation rates of water molecules in the proximities of the paramagnetic 
centre.
[3]
 
 
 
CAs based on Mn
2+
 complexes present certain potential advantages over their Gd
3+
 counterparts. Indeed, 
Mn
2+
 is an essential element present in the human body, and thus humans have developed efficient 
mechanisms to manage an excess of this ion in organs and tissues. On the contrary, Gd
3+
 is extremely toxic, 
and the release of the metal ion after the administration of certain Gd
3+
-based CAs to patients suffering from 
severe renal failure has been shown to trigger a potentially fatal disease called nephrogenic systemic fibrosis 
(NSF).
[4]
 Mn intoxication is known to promote motor and psychiatric disturbances, although the doses and 
exposure times that produce such effects are not precisely known.
[5]
 The well-known CA mangafodipir 
trisodium (Na3[Mn(dpdp)], TESLASCAN, see Scheme 1), has been used as a hepatocyte specific MRI 
contrast agent. This CA releases Mn
2+
, which is sequestered by the liver, where it is taken up and 
decomplexed by hepatocytes, allowing an enhanced contrast for diagnostic imaging of lesions in the liver 
and pancreas.
[6]
 Thus, new Mn
2+
 MRI probes sufficiently stable to minimize the release of the metal ion are 
expected to expand the potential applications of these agents. For instance, these new agents could replace 
the traditional CAs in those cases where administration of Gd
III
-based agents represents a risk for the 
patient.
[7]
 
 
 
Scheme 1. Ligands discussed in this paper. 
 
The efficiency of CAs in vitro is normally expressed in terms of their relaxivity, r1p, which is defined as the 
relaxation enhancement of water protons promoted by a 1 mM concentration of the paramagnetic metal 
ion.
[1] 
The main drawback of Mn
2+
-based CAs is their lower effective magnetic moments, which often results 
in lower relaxivities. Indeed, the relaxivities of small Mn
2+
 complexes containing one inner-sphere water 
molecule are typically 2.4–3.7 mM−1 s−1 (0.47 T, 25 °C),[8] while those of the commercially available 
Gd
3+
 CAs fall within the range 4.4–5.2 mM−1 s−1 at identical temperature and magnetic field.[1, 2] 
 
 
An obvious strategy to improve the relaxivity of Mn
2+
-based contrast agents is to increase the number of 
water molecules coordinated to the metal ion. This approach has been widely exploited to improve the 
relaxation properties of Gd
3+
-based agents, often with the use of hexa- or heptadentate ligands that leave two 
coordination positions for water ligands and still ensure a high thermodynamic stability and enough kinetic 
inertness.
[9]
 However, in some cases the relaxivity gain obtained by increasing the hydration number may be 
partially quenched by the coordination of endogenous anions to the metal ion displacing the inner-sphere 
water molecules.
[10]
 
The number of Mn
2+
-based complexes containing two coordinated water molecules so far reported as 
potential MRI CAs is scarce. Recently, Tóth et al.
[11]
 reported a series of Mn
2+
 complexes with pentadentate 
macrocyclic ligands such as 15-Py-aneN5 and 15-Py-aneO2N3 (Scheme 1) that form pentagonal bipyramidal 
Mn
2+
 complexes in solution with two water molecules occupying the axial positions. However, the relaxivity 
gain associated with the presence of two inner-sphere water molecules is quite modest, and furthermore the 
stability of the complexes was found to be relatively low. 
A second approach that can be used to attain high relaxivities consists in decreasing the tumbling rate of the 
complex, which can be achieved by covalent binding of the chelate unit to a slowly tumbling substrate such 
as a macromolecule or a nanoparticle.
[12]
 Non-covalent binding of the paramagnetic chelate to proteins such 
as human serum albumin (HSA) has been also exploited to improve the relaxation properties of the 
paramagnetic probe.
[13]
 This approach was first applied to Gd
3+
-based CAs
[14]
 and then extended to 
Mn
2+
 complexes such as the edta-derivatives bearing hydrophobic pendant groups able to promote strong 
non-covalent binding interactions with HSA ([Mn(edta-BOM)]
2−
and [Mn(edta-MS)]
3−
; Scheme 1).
[15]
 
Herein, we investigate the potential of the Mn
2+
 complex of dpama
2−
 as a CA (Scheme 2). The ligand is 
potentially pentadentate and then is expected to form mono- or bisaqua complexes with Mn
2+
. We discovered 
that this complex binds rather strongly to HSA, which results in the displacement of the water molecules 
coordinated to Mn
2+
 by donor atoms of the protein. Thus, we also prepared the binucleating analogue based 
on a meta-xylene core, mX(H2dpama)2, which was designed to target HSA with one of the dpama
2−
 units 
while leaving the second one exposed to the solvent. 
The synthesis of H2dpama was achieved in two steps by treatment of 6-chloromethylpyridine-2-carboxylic 
acid ethyl ester (1)
[16] 
with methylamine chlorohydrate in the presence of K2CO3, followed by hydrolysis of 
the ethyl ester groups in 6 M HCl (Scheme 2). The desired ligand was isolated as the chlorohydrate salt with 
a yield of 66 % over the two steps. This represents a 2.6-fold increase with respect to the yield reported 
previously for the analogous ligand derived from ethylamine.
[17]
 Ligand mX(H2dpama)2 was prepared in 
76 % yield following a similar procedure by treatment of 1 with 1,3-phenylenedimethanamine (3) followed 
by acid hydrolysis of the ester groups. Treatment of H2dpama and mX(H2dpama)2 with Mn(ClO4)2⋅6 H2O in 
the presence of triethylamine resulted in the formation of the charge neutral complexes 
[Mn(dpama)(H2O)2]⋅2 H2O and [mX(Mn(dpama)(H2O)2)2]⋅6 H2O, respectively, which were isolated in 65 % 
yield. The high-resolution mass spectra (ESI
+
) and analytical data confirm the formation of the desired 
neutral complexes (see the Supporting Information). 
The relaxivity (r1p) measured for [Mn(dpama)] at 20 MHz and 298 K (pH 7.3) amounts to 5.32 mM
−1 s−1, a 
value that is about 60 % higher than those measured under the same conditions for small Mn2+complexes 
containing one coordinated water molecule (i.e., r1p=3.3 mM
−1 s−1 for [Mn(edta)]2−, Figure 1).[8] Interestingly, 
the relaxivity measured for [Mn(dpama)] is also higher than those determined for bis(aquated) seven-
coordinate Mn
2+
 complexes with neutral pentadentate macrocyclic ligands (r1p=3.5–4.5 mM
−1 s−1, 20 MHz, 
25 °C),[11] or most commercially available Gd3+-based contrast agents (r1p=4–5 mM
−1 s−1, 20 MHz, 
25 °C).[1] A further improvement of the relaxivity is observed for [mX(Mndpama)2], which presents 
a r1p value (8.63 mM
−1 s−1, 20 MHz, 25 °C) higher than those typically observed for small Gd3+ bisaqua 
complexes such as Gd(do3a) and Gd(aazta)
−
.
[9f] 
The high relaxivity values determined for [Mn(dpama)] and 
 
 
[mX(Mndpama)2] can only be explained by the presence of two water molecules in the inner coordination 
sphere of the metal ion. 
 
 
Scheme 2. Synthesis of the ligands. 
 
 
 
Figure 1. Plot of the relaxivity, r1p, for selected Gd
3+
 and Mn
2+
 complexes at 20 MHz and 298 K. 
 
 
Aiming to obtain information on the solution structure of the [Mn(dpama)(H2O)2] complex we turned our 
attention to theory. In previous works we have shown that an adequate treatment of the solvation effects in 
Mn
2+
 and Gd
3+
 complexes containing coordinated water molecules can be achieved by using DFT 
calculations and a mixed cluster/continuum approach treating explicitly the most important hydrogen-
bonding interaction between the coordinated water molecule(s) and second-sphere water molecules.
[8] 
Thus, 
we performed geometry optimizations of the [Mn(dpama)(H2O)2]⋅4 H2O system in aqueous solution at the 
TPSSh/SVP level. The optimized structure (Figure 2) shows that the dpama ligand provides five donor atoms 
arranged in a rather planar fashion (rms deviation from planarity 0.056 Å), which leaves two coordination 
positions for water molecules above and below the ligand mean plane. The metal coordination environment 
can be described as pentagonal bipyramidal, where the five donor atoms of the ligand describe the equatorial 
plane and water molecules occupy the apical positions. The calculated Mn–Owater lengths (2.21 Å) are close 
to those observed for a related Mn
2+
complexes.
[8]
 
 
 
Figure 2. Optimized geometry of the [Mn(dpama)(H2O)2]⋅4 H2O complex obtained with DFT calculations  
performed in aqueous solution at the TPSSh/SVP level. Average bond lengths [Å] of the Mn
II
 coordination 
environment: Mn–Owater 2.205(1); Mn–OCOO 2.335(64); Mn–Namine 2.569; Mn–NPY 2.287(9). 
 
The stability of the [Mn(dpama)] complex was first assessed by measuring its proton relaxivity (25 °C, 20 
MHz) as a function of pH. The relaxivity remains constant within a rather wide pH range from 10.3 to 5.5, 
while below pH∼5.5, r1p increases due to the stepwise dissociation of the complex and gradual Mn
2+
 release 
(see the Supporting Information). The stability over time of [Mn(dpama)] was assessed by relaxometric 
measurement (0.47 T, 37 °C) of a 0.98 mM solution of the complex in a lyophilized serum of human origin 
(Seronorm), which is normal human serum without added preservatives and therefore contains endogenous 
levels of the different serum components. The complex proved to be stable at least over 140 h (see the 
Supporting Information), as only very small and negligible fluctuations in the relaxation rate data were 
detected, well within the experimental error (±3–4 %). 
The proton relaxivity measured in Seronorm at 0.47 T and 37 °C (11.14 mM−1 s−1) was found to be 
considerably higher than that observed in pure water (4.17 mM
−1 s−1). This prompted us to investigate the 
interaction of the complex with HSA, which is the most common protein present in human blood plasma, 
through the well-established proton relaxation enhancement technique (see the Supporting 
Information).
[14a]
 Addition of HSA to an aqueous solution of [Mn(dpama)] (0.285 mM, pH 7.2, 310 K) 
 
 
induces a significant increase of the observed longitudinal relaxation rate of water proton nuclei of the 
solution (Figure 3). 
 
 
Figure 3. Changes in the observed longitudinal relaxation rates of water protons detected upon addition of HSA to 
solutions of the [Mn(dpama)] (0.285 mM) and [mX(Mndpama)2] (0.151 mM) complexes. The solid lines represent the 
least-squares fits of the data according to a 1:1 binding isotherm. 
 
The least-squares fit of the relaxometric titration data provide an association constant of 3372(±138) M−1, 
with a calculated relaxivity for the fully bound form of 12.2(±0.8) mM
−1 s−1. The 1H nuclear magnetic 
relaxation dispersion (NMRD) obtained for the fully bound form presents a peak in the region 8–60 MHz, 
which is characteristic of slowly tumbling systems with long rotational correlation times (Figure 4). This 
confirms that [Mn(dpama)] binds to HSA, which slows down the rotation of the complex in solution. 
However, the overall relaxivity determined for the fully bound form is relatively low when compared to 
other Mn
2+
 complexes that bind HSA,
[15] 
with a rather small relaxivity gain with respect to that of the 
complex in pure water. Moreover, the peak in the NMRD profile is rather broad and significantly lower than 
that typical of paramagnetic adducts with HSA. Rather, the shape of the profile and the value 
of r1p corresponding to the maximum of the peak are more similar to those of q=0 Gd
3+
 and Mn
2+
 chelates 
bound to HSA.
[14b, 15a]
 This suggests that protein binding results in the replacement of the two water 
molecules coordinated to Mn
2+
 by donor groups contained in residues of the protein.
[18] 
In light of the results 
obtained for [Mn(dpama)], we hypothesized that a dimeric analogue of this complex could bind HSA while 
leaving a complex unit exposed to the solvent, which should result in a sizeable inner-sphere contribution 
to 
1
H relaxivity. 
DFT calculations performed on the [(mX(Mndpama)(H2O)2⋅4 H2O)2] system provide bond lengths of the 
metal coordination environment very similar to those of the mononuclear analogue, the Mn⋅⋅⋅Mn distance 
being about 10.8 Å. The 
1
H NMRD profile of [mX(Mndpama)2] is characteristic of a Mn
2+
complex with a 
low molecular weight, with a single dispersion at 1–10 MHz. Titration of 0.151 mMsolution of 
[mX(Mndpama)2] with HSA (pH 7.2, 37 °C) indeed confirmed the binding of the complex to the protein with 
an association constant of 1125(±35) M−1 (Figure 3). This association constant is somewhat lower than that 
obtained for [Mn(dpama)], which indicates that the association with the protein is hindered by the presence 
of the mX(Mndpama) unit. However, the relaxivity of the fully bound form at 20 MHz and 37 °C (39.0 
(±1.3) mM
−1 s−1) is very high, confirming that one of the (Mndpama) moieties is exposed to the solvent 
 
 
providing a significant response in terms of relaxivity. Furthermore, the NMRD profile obtained for the fully 
bound form (Figure 4) is characteristic of a slowly tumbling species with sizeable inner-sphere contribution 
to relaxivity. It should be noted that this value of r1p represents an average between that of a Mn
2+
 ion 
with q=0, which contributes to the relaxivity with only the outer- and second-sphere mechanisms, and that of 
a q=2 Mn
2+
 ion, the contribution of which (inner-sphere) is largely dominant. Assuming in first 
approximation that the contribution of the q=0 Mn
2+
 is similar to that of [Mn(dpama)]–HSA (12.2 mM−1 s−1), 
then we can estimate a relaxivity for the second Mn
2+
 of about 66 mM
−1 s−1. 
 
 
Figure 4. NMRD profiles recorded at 37 °C for the [Mn(dpama)] and [mX(Mndpama)2] complexes and their fully 
bound forms to HSA. The break in the ordinate axis was introduced for better visualization. 
 
In conclusion, we have designed a pentadentate ligand for stable Mn
2+
 complexation that leaves two 
coordination positions for water molecules and shows a relatively high relaxivity when compared to other 
small Mn
2+
 and Gd
3+
 chelates. This complex interacts with HSA, which results in the displacement of the 
coordinated water molecules and therefore in a limited relaxivity gain. This prompted us to prepare a 
binucleating analogue that shows an improved relaxivity in aqueous media. The binuclear complex also 
binds HSA while retaining the coordinated water molecules in one of the Mn
2+
 centres, which results in high 
relaxivities. This ditopic complex shows that it is possible to develop low molecular weight Mn
2+
 chelates 
that may represent viable alternatives to Gd-based MRI probes. Its relaxometric properties both in the free 
form and bound to HSA are fully comparable or better than those of Gd
3+
 complexes commonly used in the 
clinical practice. The synthesis of new derivatives with improved relaxation properties as well as a detailed 
physicochemical characterization of these systems is currently in progress. 
 
Experimental Section 
General 
Chemicals were purchased from commercial sources and used without further purification. SiO2 (Fluka, pore 
size 60 Å, 70–230 mesh) was used for preparative column chromatography. 1H and 13C NMR spectra were 
recorded at 25 °C on a Bruker Avance 500 MHz spectrometer. High resolution ESI-TOF mass spectra were 
recorded using a LC-Q-q-TOF Applied Biosystems QSTAR Elite spectrometer in the positive mode. 
 
 
Elemental analyses were carried out on a ThermoQuest Flash EA 1112 elemental analyser. IR spectra were 
recorded using a Bruker Vector 22 spectrophotometer equipped with a Golden Gate attenuated total 
reflectance (ATR) accessory (Specac). 
1
H relaxivity 
The water proton longitudinal relaxation rates as a function of temperature (20 MHz) were measured with a 
Stelar Spinmaster spectrometer FFC-2000 (Mede, PV, Italy) on about 0.6–2.0 mM aqueous solutions in 
nondeuterated water. The exact concentrations of Mn
II
 ions were determined by measurement of bulk 
magnetic susceptibility shifts of a tBuOH signal on a Bruker Avance III spectrometer (11.7 T). 
The 
1
H T1 relaxation times were acquired by the standard inversion recovery method with typical 90° pulse 
width of 3.5 μs, 16 experiments of four scans. The reproducibility of the T1 data was ±5 %. The temperature 
was controlled with a Stelar VTC-91 airflow heater equipped with a calibrated copper-constantan 
thermocouple (uncertainty of ±0.1 °C). The proton 1/T1 NMRD profiles were measured on a fast field-
cycling Stelar SmartTracer relaxometer over a continuum of magnetic field strengths from 0.00024–0.25 T 
(corresponding to 0.01–10 MHz proton Larmor frequencies). The relaxometer operates under computer 
control with an absolute uncertainty in 1/T1 of ±1 %. Additional data points in the range 15–70 MHz were 
obtained on a Bruker WP80 NMR electromagnet adapted to variable-field measurements (15–80 MHz 
proton Larmor frequency) using a Stelar console. 
Diethyl 6,6′-((methylazanediyl)bis(methylene))dipicolinate (2) 
6-Chloromethylpyridine-2-carboxylic acid ethyl esther
[16] 
(6.40 g, 32.1 mmol) and K2CO3 (6.77 g, 49.0 
mmol) were added to a solution of MeNH2⋅HCl (1.00 g, 14.8 mmol) in acetonitrile (50 mL). The mixture 
was stirred at 45 °C for a period of 4 days and after this, was heated to reflux for 1 day. The excess of 
K2CO3 was filtered off, the filtrate was concentrated to dryness, and the orange residue was extracted with a 
mixture of H2O and CHCl3 (1:3; 200 mL). The organic phase was evaporated to dryness to give an oily 
residue that was purified by column chromatography on SiO2 with a CH2Cl2/MeOH 5 % mixture as the 
eluent to give 4.85 g of 2 as an orange oil. Yield: 74 %; elemental analysis calcd (%) for C19H23N3O4⋅CH2Cl2: 
C 54.31, H 5.70, N 9.50; found: C 54.52, H 5.54, N 9.36; HR-MS (ESI
+
, MeOH/CH3CN/H2O 
9:1:1): m/z calcd for [C19H24N3O4]
+
: 358.1761; found: 358.1757; IR (ATR): =1736, 1714 cm
−1
 (C O); 
1
H 
NMR (CDCl3, 500 MHz, 25 °C, TMS): δ=7.99 (dd, 2 H, 
3
J=6.7 Hz,
4
J=2.0 Hz), 7.81 (m, 4 H), 4.47 (c, 
4 H, 3J=7.2 Hz), 3.91 (s, 4 H), 2.34 (s, 3 H), 1.43 ppm (t, 6 H, 3J=7.2 Hz); 13C NMR (CDCl3, 125.8 MHz, 
25 °C, TMS): δ=165.3, 160.1, 147.7, 137.3, 125.9, 123.5, 63.2, 61.8, 42.7, 14.3 ppm. 
6,6′-((Methylazanediyl)bis(methylene))dipicolinic acid (H2dpama⋅2 HCl) 
A solution of compound 2 (1.10 g, 2.49 mmol) in 6 M HCl (50 mL) was heated to reflux for 24 h, and then 
the solvent was removed in a rotary evaporator to give a yellow oil. A small amount of H2O was added (∼20 
mL) and the mixture evaporated to dryness. This process was repeated once with addition of water and twice 
with addition of diethyl ether (∼20 mL) to give 0.825 g of the desired ligand as a dark-yellow solid. Yield: 
89 %; elemental analysis calcd (%) for C15H15N3O4⋅2 HCl: C 48.14, H 4.58, N 11.23; found: C 47.86, H 4.58, 
N 10.92; MS (ESI
+
, MeOH/CH3CN/H2O 9:1:1): m/z: 340 [C15H15KN3O4]
+
; IR (ATR): =1726 cm
−1
 (C
O); 
1
H NMR (D2O, pD 1.8, 500 MHz, 25 °C, TMS): δ=7.93 (d, 2 H, 
3
J=7.8 Hz), 7.87 (t, 2 H, 3J=7.8 Hz), 
7.53 (d, 2 H, 3J=7.8 Hz), 4.62 (s, 4 H), 3.09 ppm (s, 3 H); 13C NMR (D2O, pD 1.8, 125.8 MHz, 25 °C, 
TMS): δ=167.2, 149.7, 146.8, 139.7, 128.3, 125.3, 60.3, 43.0 ppm. 
[Mn(dpama)(H2O)2]⋅(H2O)2 
A solution of H2dpama⋅2 HCl (0.100 g, 0.267 mmol), triethylamine (0.108 g, 1.07 mmol) and 
Mn(ClO4)2⋅6 H2O (0.097 g, 0.267 mmol) in 2-propanol (10 mL) under argon atmosphere was stirred at room 
temperature for 24 h, which resulted in the formation of a white solid. This was isolated by filtration, washed 
 
 
with 2-propanol and diethyl ether, and dried under vacuum. Yield 0.074 g, 65 %; elemental analysis calcd. 
(%) for C15H13MnN3O4⋅4 H2O: C 42.26, H 4.97, N 9.86; found: C 41.84, H 5.22, N 9.98; HR-MS (ESI
+
, 
MeOH/CH3CN/H2O 9:1:1): m/z calcd for [C15H14MnN3O4]
+
: 355.0359; found: 355.0359; IR (ATR): =1620, 
1586 cm
−1
 (C O). 
Tetraethyl 6,6′,6′′,6′′′-(((1,3-phenylenebis(methylene))bis(azanetriyl))tetrakis(methylene))tetrapicolinate (4) 
6-Chloromethylpyridine-2-carboxylic acid ethyl ester 1 (6.16 g, 30.8 mmol) and K2CO3 (6.70 g, 48.5 mmol) 
were added to a solution of 1,3-phenylenedimethanamine (1.00 g, 7.34 mmol) in acetonitrile (100 mL). The 
mixture was stirred for a period of 4 days at 45 °C and after this was heated to reflux for 1 day. The excess of 
K2CO3 was filtered off, the filtrate was concentrated to dryness, and the yellow residue was extracted with a 
mixture of H2O and CHCl3 (1:3; 200 mL). The organic phase was evaporated to dryness to give an oily 
residue that was purified by column chromatography on SiO2with a CH2Cl2/MeOH 5 % mixture as the eluent 
to give 6.27 g of 2 as a yellow oil. Yield: 82 %; elemental analysis calcd (%) for C44H48N6O8⋅3CH2Cl2: C 
54.09, H 5.22, N 8.05; found: C 54.32, H 5.44, N 7.82; HR-MS (ESI
+
, MeOH/CH3CN/H2O 9:1:1): m/z calcd 
for [C44H49N6O8]
+
: 789.3606; found: 789.3607; IR (ATR): =1714 cm
−1
 (C O); 
1
H NMR (CDCl3, 500 
MHz, 25 °C, TMS): δ=7.96 (m, 4 H), 7.80 (m, 8 H), 7.34 (m, 4 H), 4.45 (c, 8 H, 3J=7.1 Hz), 3.92 (s, 8 H), 
3.70 (s, 4 H), 1.41 ppm (t, 12 H, 3J=7.1 Hz); 13C NMR (CDCl3, 125.8 MHz, 25 °C, TMS): δ=165.2, 160.3, 
147.7, 138.8, 137.3, 129.3, 128.4, 127.8, 125.7, 123.4, 61.8, 59.6, 58.6, 14.3 ppm. 
6,6′,6′′,6′′′-(((1,3-Phenylenebis(methylene))bis(azanetriyl))tetrakis(methylene))tetrapicolinic acid 
(mX(H2dpama)2⋅7 HCl⋅H2O) 
A solution of compound 2 (1.00 g, 0.958 mmol) in 6 M HCl (50 mL) was heated to reflux for 24 h and then 
the solvent was removed in a rotary evaporator to give a yellow oil. A small amount of H2O was added (∼20 
mL) and the mixture evaporated to dryness. This process was repeated once with addition of another portion 
of H2O and twice with addition of diethyl ether (∼20 mL) to give 0.846 g of the desired ligand as a light-
yellow solid. Yield: 93 %; elemental analysis calcd (%) for C36H32N6O8⋅7 HCl⋅H2O: C 45.52, H 4.35, N 8.85; 
found: C 45.22, H 4.54, N 8.91; MS (ESI
+
, MeOH/CH3CN/H2O 9:1:1): m/z: 677 [C36H33N6O8]
+
; IR (ATR): 
=1730, 1707 cm
−1
 (C O); 
1
H NMR (D2O, pD 7.0, 500 MHz, 25 °C, TMS): δ=7.72–7.19 (m, 16 H), 4.24 (s, 
8 H), 4.20 ppm (s, 4 H); 13C NMR (D2O, pD 7.0, 125.8 MHz, 25 °C, TMS): δ=171.8, 152.4, 151.9, 138.8, 
138.7, 132.4, 131.5, 129.4, 125.9, 123.3, 59.5, 58.8 ppm. 
[mX(Mn(dpama)(H2O)2)2]⋅(H2O)6 
A solution of mX(H2dpama)2⋅7 HCl⋅H2O (0.100 g, 0.105 mmol), triethylamine (0.117 g, 1.16 mmol) and 
Mn(ClO4)2⋅6 H2O (0.076 g, 0.210 mmol) in 2-propanol (10 mL) was stirred at room temperature for 24 h 
under argon atmosphere; this resulted in the formation of a white solid which was isolated by filtration. The 
solid was then suspended in acetonitrile (10 mL) and stirred at room temperature for 24 h under argon. The 
solid was isolated by filtration, washed with acetonitrile and diethyl ether, and dried under vacuum. Yield 
0.066 g, 65 %; elemental analysis calcd. (%) for C36H28Mn2N6O8⋅10 H2O: C 44.92, H 5.03, N 8.73; found: C 
44.91, H 4.82, N 8.79; HR-MS (ESI
+
, MeOH/CH3CN/H2O 9:1:1): m/z calcd for [C36H28Mn2N6NaO8]
+
: 
805.0621; found: 805.0627; IR (ATR): =1622, 1587 cm
−1
 (C O). 
DFT calculations 
Full geometry optimizations of the [Mn(dpama)(H2O)2]⋅4 H2O and [(mX(Mndpama)(H2O)2⋅4 H2O)2] systems 
were performed in aqueous solution at the TPSSh/SVP
[19, 20]
 level employing the Gaussian 09 package 
(Revision B.01).
[21] 
The stationary points found on the potential energy surfaces as a result of geometry 
optimizations were tested to represent energy minima rather than saddle points via frequency analysis. 
Solvent effects were included by using the polarizable continuum model (PCM), in which the solute cavity is 
 
 
built as an envelope of spheres centred on atoms or atomic groups with appropriate radii. In particular, the 
integral equation formalism (IEFPCM) variant as implemented in Gaussian 09 was used.[22] 
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